Cat. No.: HY-19725

A-1155463

24 Cited Publications

Avis client

Based on 24 publication(s) in Google Scholar

A-1155463, a chemical probe, is a highly potent and selective BCL-XL inhibitor with an EC₅₀ of 70 nM in Molt-4 cell. A-1155463 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 98.97%
CAS No.: 1235034-55-5
Formule: C₃₅H₃₂FN₅O₄S₂
Masse moléculaire:669.79

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

A-1155463 Chemical Structure

CAS No.: 1235034-55-5

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (24)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target^[2]

Bcl-xL

0.01 nM (Ki)

Bcl-2

80 nM (Ki)

Voir tous les produits spécifiques à Isoform Bcl-2 Family :

Cellular Effect

Cell Line	Type	Value	Description	References
DMS-79	EC₅₀	1.44 μM Compound: A-1155463	Antiproliferative activity against human DMS 79 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human DMS 79 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
EOL1	EC₅₀	2.25 μM Compound: A-1155463	Antiproliferative activity against human EOL1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human EOL1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
GDM-1	EC₅₀	1.17 μM Compound: A-1155463	Antiproliferative activity against human GDM-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human GDM-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
HEL	EC₅₀	0.12 μM Compound: A-1155463	Antiproliferative activity against human HEL harboring JAK2 V617F mutant assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human HEL harboring JAK2 V617F mutant assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
HL-60	EC₅₀	>5 μM Compound: A-1155463	Antiproliferative activity against human HL-60 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human HL-60 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
Kasumi 1	EC₅₀	0.011 μM Compound: A-1155463	Antiproliferative activity against human Kasumi 1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human Kasumi 1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
KG-1	EC₅₀	>5 μM Compound: A-1155463	Antiproliferative activity against human KG-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human KG-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
ML-2	EC₅₀	>5 μM Compound: A-1155463	Antiproliferative activity against human ML-2 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human ML-2 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
MOLM-13	EC₅₀	>5 μM Compound: A-1155463	Antiproliferative activity against human MOLM-13 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human MOLM-13 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
MOLM-16	EC₅₀	>5 μM Compound: A-1155463	Antiproliferative activity against human MOLM16 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human MOLM16 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
MOLT-4	EC₅₀	>5000 nM Compound: A-1155463	Antiproliferative activity against Bcl-2 dependent human MOLT-4 cells assessed as reduction in cell viability by measuring effect concentration by CellTiter-Glo reagent based assay Antiproliferative activity against Bcl-2 dependent human MOLT-4 cells assessed as reduction in cell viability by measuring effect concentration by CellTiter-Glo reagent based assay	[PMID: 25787766]
MOLT-4	EC₅₀	70 nM Compound: 32; A-1155463	Cytotoxicity against human Bcl-XL dependant MOLT4 cells by cell based assay Cytotoxicity against human Bcl-XL dependant MOLT4 cells by cell based assay	[PMID: 26988306]
MOLT-4	EC₅₀	70 nM Compound: A-1155463	Antiproliferative activity against Bcl-xl dependent human MOLT-4 cells assessed as reduction in cell viability by measuring effect concentration by CellTiter-Glo reagent based assay Antiproliferative activity against Bcl-xl dependent human MOLT-4 cells assessed as reduction in cell viability by measuring effect concentration by CellTiter-Glo reagent based assay	[PMID: 25787766]
MOLT-4	IC₅₀	6.2 nM Compound: A-1155463	Cytotoxicity against human MOLT-4 cells assessed as cell growth inhibition incubated for 72 hrs Cytotoxicity against human MOLT-4 cells assessed as cell growth inhibition incubated for 72 hrs	[PMID: 35182816]
MV4-11	EC₅₀	>5 μM Compound: A-1155463	Antiproliferative activity against human MV4-11 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human MV4-11 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H1048	EC₅₀	>10 μM Compound: A-1155463	Antiproliferative activity against human NCI-H1048 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H1048 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H1417	EC₅₀	0.007 μM Compound: A-1155463	Antiproliferative activity against human NCI-H1417 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H1417 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H146	EC₅₀	0.065 μM Compound: 17, A-1155463	Cytotoxicity against BCL-XL-dependent human NCI-H146 cells in presence of 10% human serum incubated for 48 hrs by Cell titerGlo reagent based assay Cytotoxicity against BCL-XL-dependent human NCI-H146 cells in presence of 10% human serum incubated for 48 hrs by Cell titerGlo reagent based assay	[PMID: 25313317]
NCI-H1836	EC₅₀	0.015 μM Compound: A-1155463	Antiproliferative activity against human NCI-H1836 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H1836 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H187	EC₅₀	0.18 μM Compound: A-1155463	Antiproliferative activity against human NCI-H187 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H187 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H211	EC₅₀	1.35 μM Compound: A-1155463	Antiproliferative activity against human NCI-H211 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H211 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H345	EC₅₀	>10 μM Compound: A-1155463	Antiproliferative activity against human NCI-H345 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H345 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H446	EC₅₀	0.2 μM Compound: A-1155463	Antiproliferative activity against human NCI-H446 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H446 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H69	EC₅₀	3.2 μM Compound: A-1155463	Antiproliferative activity against human NCI-H69 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H69 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NCI-H889	EC₅₀	6.31 μM Compound: A-1155463	Antiproliferative activity against human NCI-H889 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NCI-H889 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
NOMO-1	EC₅₀	>5 μM Compound: A-1155463	Antiproliferative activity against human NOMO-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human NOMO-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
OCI-AML2	EC₅₀	>5 μM Compound: A-1155463	Antiproliferative activity against human OCI-AML2 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human OCI-AML2 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
OCI-AML-3	EC₅₀	>5 μM Compound: A-1155463	Antiproliferative activity against human OCI-AML-3 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human OCI-AML-3 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
OCI-AML-5	EC₅₀	>5 μM Compound: A-1155463	Antiproliferative activity against human OCI-AML5 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human OCI-AML5 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
Platelet	IC₅₀	7.1 nM Compound: A-1155463	Cytotoxicity against human platelets assessed as cell growth inhibition incubated for 24 hrs Cytotoxicity against human platelets assessed as cell growth inhibition incubated for 24 hrs	[PMID: 35182816]
RS4-11	EC₅₀	>5 μM Compound: 32; A-1155463	Cytotoxicity against human Bcl-2 dependant RS4:11 cells by cell based assay Cytotoxicity against human Bcl-2 dependant RS4:11 cells by cell based assay	[PMID: 26988306]
SET-2	EC₅₀	0.08 μM Compound: A-1155463	Antiproliferative activity against human SET2 harboring JAK2 V617F mutant assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human SET2 harboring JAK2 V617F mutant assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
SIG-M5	EC₅₀	>5 μM Compound: A-1155463	Antiproliferative activity against human SIG-M5 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human SIG-M5 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
SKM-1	EC₅₀	>5 μM Compound: A-1155463	Antiproliferative activity against human SKM-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human SKM-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]
THP-1	EC₅₀	>5 μM Compound: A-1155463	Antiproliferative activity against human THP-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay Antiproliferative activity against human THP-1 assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo cell vaibility assay	[PMID: 25787766]

In Vitro

A-1155463 shows picomolar binding affinity to BCL-X_L (K_i＜0.01 nM), and >1000-fold weaker binding to BCL-2 (K_i= 80 nM) and related proteins BCL-W (K_i= 19 nM) and MCL-1 (K_i> 440 nM) ^[2].
A-1155463 demonstrates strong growth inhibition of over half of the colorectal cell lines as defined by EC₅₀ values ≤0.5 μM in the presence of 10 % FBS^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

A-1155463 caused a mechanism-based and reversible thrombocytopenia in mice and inhibited H146 small cell lung cancer xenograft tumor growth in vivo following multiple doses^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1235034-55-5
Appearance Solid
Masse moléculaire 669.79
Formule C₃₅H₃₂FN₅O₄S₂
Color Off-white to yellow
SMILES

O=C(C1=C(CCCOC2=CC=C(C#CCN(C)C)C=C2F)SC(N3CC4=C(C=CC=C4C(NC5=NC6=CC=CC=C6S5)=O)CC3)=N1)O
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (24)

All Cell Proliferation/Viability AssayBio/Physico-chemical AssayFlow Cytometry

Sort by:

Journal Impact Factor

J Hematol Oncol

DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. [Abstract]

2020 Jul 16;13(1):95. PMID: 32677976

A-1155463 purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2020 Jul 16;13(1):95. [Abstract]

The viability of DFTL-28776 PDX cells was determined after A-1155463 (0.001-10 μM; 24 h) treatment.
Nat Commun

Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]

2026 Feb 12;17(1):1214. PMID: 41680175
J Clin Invest

BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo. [Abstract]

2020 May 1;130(5):2542-2559. PMID: 32027622
Pharmacol Res

Combination of palbociclib with navitoclax based-therapies enhances in vivo antitumoral activity in triple-negative breast cancer. [Abstract]

2023 Jan:187:106628. PMID: 36566002
Cell Death Dis

XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis. [Abstract]

2019 May 21;10(6):395. PMID: 31113936

A-1155463 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 May 21;10(6):395. [Abstract]

U87, U251, H1299, and A549 cells were treated with KPT-330 (1 μM) for 24 h and further with A-1155463 (1 μM; 24 h), then subjected to western blot or flow cytometry analysis for the sub-G1 phase.

A-1155463 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 May 21;10(6):395. [Abstract]

A-1331852 (1 μM; 48 h). Cell viability was measured by the MTT assay.

A-1155463 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 May 21;10(6):395. [Abstract]

The mitochondrial membrane potential in U251 cells treated with A-1155463 (1 μM; 24 h) was measured by flow cytometry.
Cell Death Discov

Exploiting dysregulated iron homeostasis to eradicate persistent high-grade serous ovarian cancer. [Abstract]

2025 Sep 25;11(1):423. PMID: 40998801
Cell Death Discov

Long-term adaptation of lymphoma cell lines to hypoxia is mediated by diverse molecular mechanisms that are targetable with specific inhibitors. [Abstract]

2025 Feb 18;11(1):65. PMID: 39966387
Oncogene

Mouse ER+/PIK3CAH1047R breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents. [Abstract]

2019 Jan;38(1):47-59. PMID: 30076411
Leukemia

BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML. [Abstract]

2025 Dec 19. PMID: 41419608

A-1155463 purchased from MedChemExpress. Usage Cited in: Leukemia. 2025 Dec 19. [Abstract]

A-1155463 (1-100 nM; 48 h) dose-dependently induced lethality in PD AML cells.
Stem Cell Res Ther

Thymosin beta-4 improves endothelial function and reparative potency of diabetic endothelial cells differentiated from patient induced pluripotent stem cells. [Abstract]

2022 Jan 10;13(1):13. PMID: 35012642
Blood Adv

Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. [Abstract]

2019 Dec 23;3(24):4202-4214. PMID: 31856269
Biochem Pharmacol

BCL2L1 inhibitor A-1331852 inhibits MCL1 transcription and triggers apoptosis in acute myeloid leukemia cells. [Abstract]

2023 Sep:215:115738. PMID: 37562509
Cells

Study of the Bcl-2 Interactome by BiFC Reveals Differences in the Activation Mechanism of Bax and Bak. [Abstract]

2023 Mar 3;12(5):800. PMID: 36899936
Comput Struct Biotechnol J

A deep tabular data learning model predicting cisplatin sensitivity identifies BCL2L1 dependency in cancer. [Abstract]

2023 Jan 16:21:956-964. PMID: 36733702
Mol Oncol

Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-XL in multiple myeloma cell lines partially-dependent on MCL-1 and in plasma cells from patients. [Abstract]

2023 Dec;17(12):2507-2525. PMID: 37704591
J Photochem Photobiol B

Differential UVC radiation sensitivity in multidrug-resistant l1210 cells: Insights into p53 and Bcl-XL expression/function. [Abstract]

2025 Oct:271:113229. PMID: 40752104
Immunol Cell Biol

Inflammatory compound lipopolysaccharide promotes the survival of GM-CSF cultured dendritic cell via PI3 kinase-dependent upregulation of Bcl-x. [Abstract]

2018 Oct;96(9):912-921. PMID: 29624724
Immunopharmacol Immunotoxicol

Astragaloside IV restores Th17/Treg balance via inhibiting CXCR4 to improve chronic obstructive pulmonary disease. [Abstract]

2023 Dec;45(6):682-691. PMID: 37417915
J Cell Biochem

Mcl-1 is a Gatekeeper Molecule to Regulate the Crosstalk Between Ferroptotic Agent-Induced ER Stress and TRAIL-Induced Apoptosis. [Abstract]

2025 Jan;126(1):e30681. PMID: 39853862
Eur J Neurosci

Dexmedetomidine attenuates propofol-induced apoptosis of neonatal hippocampal astrocytes by inhibiting the Bcl2l1 signalling pathway. [Abstract]

2021 Dec;54(11):7775-7789. PMID: 34734676
Leuk Lymphoma

MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells. [Abstract]

2019 Sep;60(9):2170-2180. PMID: 30626241
bioRxiv

Sacituzumab Govitecan as an Effective Strategy for Sensitizing Chemoresistant HNSCC Cells to Senolytic Intervention. [Abstract]

2026 Apr 15:2026.04.13.718209. PMID: 42039381
bioRxiv

2025 April 10.
Research Square Preprint

2023 Jul 7.

Solvant et solubilité

In Vitro:

DMSO : 50 mg/mL (74.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.4930 mL

7.4650 mL

14.9301 mL

5 mM

0.2986 mL

1.4930 mL

2.9860 mL

10 mM

0.1493 mL

0.7465 mL

1.4930 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (3.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Animal Administration^[2]

Mice: Following a single 5 mg/kg IP dose of A-1155463 in nontumor bearing SCID-Beige mice, platelet counts fell dramatically as measured at 6 h postdose and then rebounded to normal levels within 72 h. A-1155463 is then administered to SCID-Beige mice that had been inoculated with BCL-XL-dependent H146 tumor cells with a daily dose at 5 mg/kg IP for 14 days^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Leverson JD, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med.?2015 Mar 18;7(279):279 [Content Brief]

[2]. Tao ZF, et al. Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. ACS Med Chem Lett. 2014 Aug 26;5(10):1088-93. [Content Brief]

[3]. Zhang H, et al. Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer. Mol Cancer. 2015 Jul 2;14:126. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.4930 mL	7.4650 mL	14.9301 mL	37.3251 mL
	5 mM	0.2986 mL	1.4930 mL	2.9860 mL	7.4650 mL
	10 mM	0.1493 mL	0.7465 mL	1.4930 mL	3.7325 mL
	15 mM	0.0995 mL	0.4977 mL	0.9953 mL	2.4883 mL
	20 mM	0.0747 mL	0.3733 mL	0.7465 mL	1.8663 mL
	25 mM	0.0597 mL	0.2986 mL	0.5972 mL	1.4930 mL
	30 mM	0.0498 mL	0.2488 mL	0.4977 mL	1.2442 mL
	40 mM	0.0373 mL	0.1866 mL	0.3733 mL	0.9331 mL
	50 mM	0.0299 mL	0.1493 mL	0.2986 mL	0.7465 mL
	60 mM	0.0249 mL	0.1244 mL	0.2488 mL	0.6221 mL

Keywords

A-1155463

24 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

A-1155463

Apoptosis Compound Library

Anti-Cancer Compound Library

Chemical Probe Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Mitochondria-Targeted Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Alkyne Compound Library

Publications Citing Use of MedChemExpress (MCE) A-1155463

Voir tous les produits spécifiques à Isoform Bcl-2 Family

Activité biologique

Chemical Information

Publications (24)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

A-1155463

Apoptosis Compound Library

Anti-Cancer Compound Library

Chemical Probe Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Mitochondria-Targeted Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Alkyne Compound Library

Publications Citing Use of MedChemExpress (MCE) A-1155463

Voir tous les produits spécifiques à Isoform Bcl-2 Family

Activité biologique

Chemical Information

Publications (24)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

A-1155463 Related Classifications

HY-19725 Related Classifications